While STAG2 mutational activation is known to be frequent in glioblastoma, Ewing sarcoma, and urothelial carcinoma, the effect of STAG2 status on the response to cytotoxic chemotherapy agents routinely used in the treatment of these cancer types is largely unknown. The gene discussed is STAG2; the disease is urothelial carcinoma.